MedpageToday
medpagetoday news
video

Frailty in CML: What are the Clinical Implications?

"Frailty is a really interesting topic," says Catherine Lai, MD, MPH, of the University of Pennsylvania. While frailty is more of an issue in acute myeloid leukemia, she cautions clinicians to carefully consider side effects when prescribing tyrosine kinase inhibitors. (1:52)
video

Measuring Disease Response in CML

In Patients with CML, Frailty—Not Age—Is a Strong Predictor of Poor Outcomes

Investigators examined the impact of frailty on hospital outcomes in patients with chronic myeloid leukemia, finding frail patients to be at 4 times the risk of in-hospital mortality.

Secondary Hematologic Malignancies on the Rise Following CLL

Utilizing data from SEER, a team of U.S.-based researchers set out to determine the real-world burden of secondary hematologic malignancies in patients with chronic lymphocytic leukemia.

In CML Patients, What Happens When Low-dose TKIs are Discontinued?

TKI dose reduction can be done in CML patients as a way to mitigate adverse events. These investigators went further, conducting a retrospective study to assess the outcome when CML patients discontinued low-dose TKIs.
medpagetoday news

CML Patients Treated with TKIs have Lower COVID-19 Fatality Rates

Investigators found that patients with CML treated with TKIs had a lower fatality rate when compared with reports in the literature, suggesting future studies of TKIs as a potential COVID-19 treatment are warranted.

Chronic Hematological Malignancies: The Caregivers Face Challenges, Too

Patients with chronic hematological malignancies bear significant physical and emotional pain—and so do their caregivers. Sometimes the strain faced by caregivers impedes the provision of quality care.